BTN1A1 Expression as a Biomarker for Patient Selection: Phase 1b IHC Analysis and Clinical Outcomes Supporting a Biomarker-Guided Phase 2 Trial in Colorectal Cancer

Nelmastobart Combination Shows Excellent Tolerability and Early Antitumor Activity in Refractory mCRC

Nelmastobart (BTN1A1 Inhibitor) Combined with Capecitabine in Metastatic Colorectal Cancer : Phase 1b/2 Study Results

BTN1A1 Blockade Enhances Chemotherapy-Induced Anti-Tumor Immunity in Preclinical Lung Cancer Models

BTN1A1 Expression Is Inversely Associated with CD8⁺ T Cell Infiltration in the Tumor Microenvironment of Lung and Colon Cancer

BTN1A1 H-Score and Multiplex Biomarker Profiling Predict Clinical Benefit from Nelmastobart plus Capecitabine in Advanced Colorectal Cancer: Phase Ib/II Study

BTN1A1-Targeted Immunotherapy Enhances Standard Treatment Efficacy in NSCLC and Colorectal Cancer: Insights from Patient-Derived Organoids and Zebrafish Models

BTN1A1 and Nuclear YAP1 Co-Expression as Predictive Biomarkers for Nelmastobart Efficacy in Lung Cancer

Targeting BTN1A1 in PD-L1–Negative NSCLC: A Clinically Actionable Immune Checkpoint for Docetaxel-Based Combination Therapy

Therapeutic Targeting of the BTN1A1-YAP1 Axis: A Novel Mechanism of Immune Evasion in Cancer